SKYRIZI 150 mg PRE-FILLED SYRINGE SOLUTION FOR INJECTION

2. What you need to know before you use Skyrizi

Do not use Skyrizi

• if you are allergic to risankizumab or any of the other ingredients of this medicine (listed in section 6).
• if you have an infection that your doctor thinks is important, for example, active tuberculosis.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you start using Skyrizi and during treatment:

• if you have a current infection or if you have an infection that keeps coming back.
• if you have tuberculosis (TB).
• if you have recently received or are scheduled to receive a vaccine. Certain vaccines should not be given during treatment with Skyrizi.

It is important to keep a copy of the batch number of Skyrizi.

Each time you receive a new pack of Skyrizi, write down the date and batch number (which appears on the pack after “Batch”) and keep this information in a safe place.

Allergic reactions

Talk to your doctor or seek medical attention right away if you notice any signs of an allergic reaction while receiving Skyrizi, such as:

• difficulty breathing or swallowing
• swelling of the face, lips, tongue, or throat
• severe itching of the skin, with a red rash or hives

Children and adolescents

Skyrizi is not recommended for children and adolescents under 18 years of age, as it has not been studied in this age group.

Other medicines and Skyrizi

Tell your doctor, pharmacist, or nurse:

• if you are using, have recently used, or might use any other medicines.
• if you have recently been vaccinated or are scheduled to be vaccinated. Certain vaccines should not be given during treatment with Skyrizi.

If in doubt, talk to your doctor, pharmacist, or nurse before using Skyrizi and during treatment.

Pregnancy, contraception, and breastfeeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. You must do this because we do not know how this medicine affects the unborn baby.

If you are a woman who can become pregnant, you must use contraception while you are being treated with this medicine and for at least 21 weeks after your last dose of Skyrizi.

If you are breastfeeding or plan to breastfeed, ask your doctor for advice before taking this medicine.

Driving and using machines

Skyrizi is unlikely to affect your ability to drive or use machines.

Skyrizi contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per pre-filled syringe, which is essentially “sodium-free”.

3. How to use Skyrizi

Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, talk to your doctor or pharmacist again.

This medicine is given by injection under the skin (called a “subcutaneous injection”).

How much Skyrizi to use

Each dose is 150 mg given as a single injection. After the first dose, the next dose will be given 4 weeks later, and then every 12 weeks.

You and your doctor, pharmacist, or nurse will decide if you can inject this medicine yourself. You should not inject this medicine yourself unless your doctor, pharmacist, or nurse has taught you how to do it. It is also possible that the injection will be given by a caregiver who has learned how to do it.

Read section 7 “Instructions for use” at the end of this leaflet before giving yourself the Skyrizi injection.

If you use more Skyrizi than you should

If you have used more Skyrizi than you should or have given yourself a dose earlier than prescribed, talk to your doctor.

If you forget to use Skyrizi

If you forget to give yourself a dose of Skyrizi, you should give yourself a dose as soon as you remember. If you are unsure, talk to your doctor.

If you stop using Skyrizi

Do not stop using Skyrizi without talking to your doctor first. If you stop treatment, your symptoms may come back.

If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Talk to your doctor or seek medical attention right away if you have any symptoms of a serious infection, such as:

• fever, flu-like symptoms, night sweats
• feeling tired or having trouble breathing, persistent cough
• heat, redness, and pain in the skin or a painful skin rash with blisters

Your doctor will decide if you can continue using Skyrizi.

Other side effects

Tell your doctor, pharmacist, or nurse if you notice any of the following side effects.

Very common:may affect more than 1 in 10 people

• upper respiratory tract infections with symptoms such as sore throat and nasal congestion

Common:may affect up to 1 in 10 people

• feeling tired
• fungal skin infections
• reactions at the injection site (such as redness or pain)
• itching
• headache
• rash
• eczema

Uncommon:may affect up to 1 in 100 people

• small red bumps on the skin
• hives (urticaria)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Skyrizi

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label of the syringe and on the outer carton after EXP.

Store in a refrigerator (between 2°C and 8°C). Do not freeze.

Keep the pre-filled syringe in the original packaging to protect it from light.

If necessary, you can also store the pre-filled syringe at room temperature (up to 25°C) for a maximum of 24 hours in the original packaging to protect it from light.

Do not use this medicine if the liquid is cloudy or contains flakes or large particles.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Contents and Additional Information

Skyrizi Composition

• The active substance is risankizumab. Each prefilled syringe contains 150 mg of risankizumab in 1 ml of solution.
• The other ingredients are sodium acetate trihydrate, acetic acid, trehalose dihydrate, polysorbate 20, and water for injectable preparations.

Product Appearance and Container Contents

Skyrizi is a clear, colorless to yellow liquid contained in a prefilled syringe with a needle protector. The liquid may contain tiny, transparent or white particles.

EACH CONTAINER CONTAINS 1 PREFILLED SYRINGE

Marketing Authorization Holder

AbbVie Deutschland GmbH & Co. KG

Knollstrasse

67061 Ludwigshafen

Germany

Manufacturer

AbbVie S.r.l.

04011 Campoverde di Aprilia

(Latina)

Italy

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Date of Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

Detailed and up-to-date information on this product is available below or on the outer packaging by scanning the QR code using a smartphone. The same information is also available on the following website:

www.skyrizi.eu

QR Code to be included

To request a copy of this leaflet in , or to listen to it in

1. Instructions for Use

Read the entire section 7 before using Skyrizi

Skyrizi Prefilled Syringe

Plunger Wings of restraint Needle cap

Syringe Body

Important Information You Should Know Before Injecting Skyrizi

• You must have received training on how to inject Skyrizi before administering an injection. If you need help, consult your doctor, pharmacist, or nurse.
• Mark the dates on a calendar to know when it's time to inject Skyrizi.
• Keep Skyrizi in its original packaging to protect the medication from light until the time of use.
• Do notinject the medication if the liquid is cloudy or contains flakes or large particles. The liquid should be clear to yellow and may contain tiny, transparent or white particles.
• Do notshake the syringe.
• Wait to remove the needle cap until the moment before injection.

Return this medication to the pharmacy

• after the expiration date (EXP) indicated.
• if the liquid has been frozen at any time (even if it has been thawed).
• if the syringe has been dropped or damaged.
• if the perforations on the box are broken.

For a more comfortable injection: Remove the box from the refrigerator and let it sit at room temperature, away from direct sunlight, for 15 to 30minutesbefore injection.

• Skyrizi should not be heated in any other way (e.g., in a microwave or hot water).
• Keep the syringe in the box until the time of injection.

Follow these steps each time you use Skyrizi